帕博利珠单抗联合二甲双胍治疗转移性头颈部癌的 II 期可行性研究
A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer.
二甲双胍联合帕博利珠单抗耐受性良好,仅出现轻度胃肠道不良事件,并展现出有前景的活性,值得在随机试验中进一步研究。
英文原题:In situ macrophage CAR programming via ROS-responsive microneedles enhances efferocytosis and promotes mucosal regeneration.
In situ macrophage CAR programming via ROS-responsive microneedles enhances efferocytosis and promotes mucosal regeneration.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
头颈部肿瘤放疗常引起严重的放射性口腔黏膜炎(RIOM),其中过量的活性氧(ROS)、巨噬细胞胞葬作用缺陷以及持续性炎症形成自我放大的病理循环,从而延迟黏膜修复。
头颈部肿瘤放疗常引起严重的放射性口腔黏膜炎(RIOM),其中过量的活性氧(ROS)、巨噬细胞胞葬作用缺陷以及持续性炎症形成自我放大的病理循环,延迟黏膜修复。当前的对症治疗不足以同时抑制氧化应激并恢复免疫介导的受损细胞清除。在此,我们开发了一种具有ROS响应性针尖的可分离微针贴片(PTC MN),用于在RIOM病灶内进行局部原位巨噬细胞编程。PTC MN由PPBA-TA-PVA水凝胶基质制成,该基质兼具内在的ROS清除能力与氧化应激触发的降解特性,并负载携带编码CAR-ectoCRT-IL-4质粒的工程化杂合纳米囊泡(HLENs-CAR)。该设计实现了基因负载纳米囊泡的局部递送、巨噬细胞靶向的基因编程,以及治疗载荷在受损黏膜中的持续滞留。在小鼠RIOM模型中,PTC MN加速了黏膜上皮再生,减少了氧化应激和炎症浸润,增强了修复性巨噬细胞反应,并减轻了纤维化相关组织重塑。在功能上,该平台增强了巨噬细胞胞葬作用,促进了IL-4相关的修复性极化,并将病灶微环境转向炎症消退和组织再生。总体而言,本研究建立了一种智能原位免疫调节策略,将ROS响应性微针递送与CAR-巨噬细胞编程相结合,为难治性黏膜损伤提供了一种潜在的治疗范式。
Radiotherapy for head and neck cancer frequently induces severe radiation-induced oral mucositis (RIOM), in which excessive reactive oxygen species (ROS), defective macrophage efferocytosis, and persistent inflammation form a self-amplifying pathological loop that delays mucosal repair. Current symptomatic treatments are insufficient to simultaneously suppress oxidative stress and restore immune-mediated clearance of damaged cells. Here, we developed a detachable microneedle patch with ROS-responsive tips (PTC MN) for localized in situ macrophage programming within RIOM lesions. The PTC MN was fabricated from a PPBA-TA-PVA hydrogel matrix, which combines intrinsic ROS-scavenging capacity with oxidative stress triggered degradation, and loaded with engineered hybrid nanovesicles (HLENs-CAR) carrying a plasmid encoding CAR-ectoCRT-IL-4. This design enabled local delivery of gene-loaded nanovesicles, macrophage-targeted genetic programming, and sustained retention of the therapeutic payload in the injured mucosa. In a murine RIOM model, PTC MN accelerated mucosal epithelial regeneration, reduced oxidative stress and inflammatory infiltration, enhanced reparative macrophage responses, and attenuated fibrosis-associated tissue remodeling. Functionally, the platform enhanced macrophage efferocytosis, promoted IL-4-associated reparative polarization, and shifted the lesion microenvironment toward inflammation resolution and tissue regeneration. Collectively, this study establishes a smart in situ immunomodulation strategy that integrates ROS-responsive microneedle delivery with CAR-macrophage programming, providing a potential therapeutic paradigm for refractory mucosal injury.
MEMBER ACCOUNT
登录成功会直接打开下一页。